Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
START-R: Dasatinib vs High-Dose Imatinib in Resistant CML
NCT00103844Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2005
- Primary completion
- Aug 2006
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 32
01
Overview
A Phase 2 trial of dasatinib in chronic myeloid leukemia (CML), sponsored by Bristol Myers Squibb. Started Feb 2005; status: completed.
02
Drugs
dasatinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT00103844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00103844.